ArticleHepatology international2014
Advancements in in vitro hepatic models: application for drug screening and therapeutics.
Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Comparison of Glioblastoma Cell Culture Platforms Based on Transcriptional Similarity with Paired Tissue.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Macrophages and the development and progression of non-alcoholic fatty liver disease.Frontiers in immunology · 2023Review
- Connexin Expression Is Altered in Liver Development ofInternational journal of molecular sciences · 2021Article
- Microengineered cell and tissue systems for drug screening and toxicology applications: Evolution ofTechnology · 2015Article
- Hepatocyte-based flow analytical bioreactor forNanobiomedicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver is one of the most complex organs in the body, performing a multitude of functions. Liver tissue engineering is a combination of various strategies that aim at generating functional liver tissue that can help restore and/or support the ailing liver as it recuperates. Conventionally, in vitro culture has involved growing cells in different media compositions or layering them on matrices largely composed of native ECM components such as collagen or Matrigel. With recent advances in technology, more sophisticated techniques are being devised that are better equipped to capture distinct features of the liver in an in vivo microenvironment. Three-dimensional (3D) cultures of liver cells in 3D scaffolds, as spheroids or cell sheets, allow for a high degree of cell-cell and cell-matrix interaction and an in vivo-like architecture. More recently, decellularized matrices have been used as scaffolds that support ideal cell-matrix interactions. Microfabrication technologies initially used to pattern semiconductors in the integrated circuit industry have grown out of this field and now encompass a variety of methods to etch patterns onto both 2D and 3D scaffolds to allow incorporation of custom-made features resembling the fluid network and organization in native liver. This improvisation permits for enhanced vascularization and oxygen diffusion to the in vitro liver tissue. In this review, we discuss the various configurations that have been implemented in the in vitro culture of liver cells and their application in liver therapeutics in the form of implantable liver tissue constructs and tools for drug screening.
Indexed as
Identifiers
26202404What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.